Tissue | Expression Dynamics | Abbreviation |
Breast | | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003596713 | Lung | AIS | cellular response to topologically incorrect protein | 21/1849 | 116/18723 | 4.52e-03 | 4.00e-02 | 21 |
GO:0090101 | Lung | AIS | negative regulation of transmembrane receptor protein serine/threonine kinase signaling pathway | 23/1849 | 131/18723 | 4.54e-03 | 4.00e-02 | 23 |
GO:190589713 | Lung | AIS | regulation of response to endoplasmic reticulum stress | 16/1849 | 82/18723 | 5.92e-03 | 4.91e-02 | 16 |
GO:007135612 | Lung | AIS | cellular response to tumor necrosis factor | 35/1849 | 229/18723 | 6.08e-03 | 4.98e-02 | 35 |
GO:004348433 | Lung | MIAC | regulation of RNA splicing | 32/967 | 148/18723 | 3.60e-12 | 9.23e-09 | 32 |
GO:004217633 | Lung | MIAC | regulation of protein catabolic process | 47/967 | 391/18723 | 6.27e-08 | 2.15e-05 | 47 |
GO:000989632 | Lung | MIAC | positive regulation of catabolic process | 54/967 | 492/18723 | 1.42e-07 | 3.64e-05 | 54 |
GO:003139723 | Lung | MIAC | negative regulation of protein ubiquitination | 18/967 | 83/18723 | 1.81e-07 | 4.02e-05 | 18 |
GO:190332133 | Lung | MIAC | negative regulation of protein modification by small protein conjugation or removal | 19/967 | 95/18723 | 3.20e-07 | 5.66e-05 | 19 |
GO:190336233 | Lung | MIAC | regulation of cellular protein catabolic process | 34/967 | 255/18723 | 3.83e-07 | 6.52e-05 | 34 |
GO:190332023 | Lung | MIAC | regulation of protein modification by small protein conjugation or removal | 32/967 | 242/18723 | 1.01e-06 | 1.40e-04 | 32 |
GO:003164723 | Lung | MIAC | regulation of protein stability | 36/967 | 298/18723 | 1.93e-06 | 2.42e-04 | 36 |
GO:003133132 | Lung | MIAC | positive regulation of cellular catabolic process | 46/967 | 427/18723 | 2.00e-06 | 2.44e-04 | 46 |
GO:004573232 | Lung | MIAC | positive regulation of protein catabolic process | 30/967 | 231/18723 | 3.16e-06 | 3.45e-04 | 30 |
GO:005125823 | Lung | MIAC | protein polymerization | 35/967 | 297/18723 | 4.69e-06 | 4.81e-04 | 35 |
GO:001905833 | Lung | MIAC | viral life cycle | 36/967 | 317/18723 | 8.00e-06 | 7.07e-04 | 36 |
GO:190290333 | Lung | MIAC | regulation of supramolecular fiber organization | 41/967 | 383/18723 | 8.33e-06 | 7.24e-04 | 41 |
GO:003227132 | Lung | MIAC | regulation of protein polymerization | 29/967 | 233/18723 | 1.06e-05 | 8.86e-04 | 29 |
GO:190305033 | Lung | MIAC | regulation of proteolysis involved in cellular protein catabolic process | 28/967 | 221/18723 | 1.07e-05 | 8.86e-04 | 28 |
GO:004325423 | Lung | MIAC | regulation of protein-containing complex assembly | 44/967 | 428/18723 | 1.11e-05 | 9.00e-04 | 44 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0502016 | Breast | Precancer | Prion disease | 95/684 | 273/8465 | 1.39e-37 | 1.46e-35 | 1.12e-35 | 95 |
hsa0513414 | Breast | Precancer | Legionellosis | 19/684 | 57/8465 | 4.62e-08 | 9.12e-07 | 6.98e-07 | 19 |
hsa030408 | Breast | Precancer | Spliceosome | 39/684 | 217/8465 | 1.44e-06 | 2.27e-05 | 1.74e-05 | 39 |
hsa0414118 | Breast | Precancer | Protein processing in endoplasmic reticulum | 33/684 | 174/8465 | 2.78e-06 | 3.83e-05 | 2.94e-05 | 33 |
hsa0491518 | Breast | Precancer | Estrogen signaling pathway | 28/684 | 138/8465 | 4.10e-06 | 5.39e-05 | 4.13e-05 | 28 |
hsa0541718 | Breast | Precancer | Lipid and atherosclerosis | 37/684 | 215/8465 | 7.64e-06 | 9.29e-05 | 7.12e-05 | 37 |
hsa0461218 | Breast | Precancer | Antigen processing and presentation | 19/684 | 78/8465 | 9.61e-06 | 1.12e-04 | 8.62e-05 | 19 |
hsa0502017 | Breast | Precancer | Prion disease | 95/684 | 273/8465 | 1.39e-37 | 1.46e-35 | 1.12e-35 | 95 |
hsa0513415 | Breast | Precancer | Legionellosis | 19/684 | 57/8465 | 4.62e-08 | 9.12e-07 | 6.98e-07 | 19 |
hsa0304013 | Breast | Precancer | Spliceosome | 39/684 | 217/8465 | 1.44e-06 | 2.27e-05 | 1.74e-05 | 39 |
hsa0414119 | Breast | Precancer | Protein processing in endoplasmic reticulum | 33/684 | 174/8465 | 2.78e-06 | 3.83e-05 | 2.94e-05 | 33 |
hsa0491519 | Breast | Precancer | Estrogen signaling pathway | 28/684 | 138/8465 | 4.10e-06 | 5.39e-05 | 4.13e-05 | 28 |
hsa0541719 | Breast | Precancer | Lipid and atherosclerosis | 37/684 | 215/8465 | 7.64e-06 | 9.29e-05 | 7.12e-05 | 37 |
hsa0461219 | Breast | Precancer | Antigen processing and presentation | 19/684 | 78/8465 | 9.61e-06 | 1.12e-04 | 8.62e-05 | 19 |
hsa0502023 | Breast | IDC | Prion disease | 102/867 | 273/8465 | 3.70e-34 | 4.01e-32 | 3.00e-32 | 102 |
hsa0491523 | Breast | IDC | Estrogen signaling pathway | 35/867 | 138/8465 | 2.55e-07 | 5.18e-06 | 3.88e-06 | 35 |
hsa0461223 | Breast | IDC | Antigen processing and presentation | 24/867 | 78/8465 | 4.61e-07 | 8.33e-06 | 6.23e-06 | 24 |
hsa0513422 | Breast | IDC | Legionellosis | 19/867 | 57/8465 | 1.89e-06 | 3.07e-05 | 2.29e-05 | 19 |
hsa0414124 | Breast | IDC | Protein processing in endoplasmic reticulum | 36/867 | 174/8465 | 2.73e-05 | 2.86e-04 | 2.14e-04 | 36 |
hsa0304023 | Breast | IDC | Spliceosome | 40/867 | 217/8465 | 1.53e-04 | 1.42e-03 | 1.06e-03 | 40 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
HSPA1A | SNV | Missense_Mutation | novel | c.14C>T | p.Ala5Val | p.A5V | P0DMV8 | protein_coding | tolerated_low_confidence(0.15) | benign(0) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
HSPA1A | SNV | Missense_Mutation | novel | c.1694C>T | p.Ala565Val | p.A565V | P0DMV8 | protein_coding | tolerated_low_confidence(0.08) | benign(0.146) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
HSPA1A | SNV | Missense_Mutation | novel | c.1451G>T | p.Gly484Val | p.G484V | P0DMV8 | protein_coding | deleterious_low_confidence(0) | probably_damaging(1) | TCGA-NH-A5IV-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
HSPA1A | SNV | Missense_Mutation | novel | c.1690N>A | p.Glu564Lys | p.E564K | P0DMV8 | protein_coding | tolerated_low_confidence(0.08) | benign(0.022) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
HSPA1A | SNV | Missense_Mutation | novel | c.1841N>T | p.Ala614Val | p.A614V | P0DMV8 | protein_coding | deleterious_low_confidence(0.03) | benign(0.031) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
HSPA1A | SNV | Missense_Mutation | | c.1876N>T | p.Gly626Cys | p.G626C | P0DMV8 | protein_coding | deleterious_low_confidence(0.05) | possibly_damaging(0.455) | TCGA-AP-A05N-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
HSPA1A | SNV | Missense_Mutation | novel | c.1625N>C | p.Leu542Pro | p.L542P | P0DMV8 | protein_coding | deleterious_low_confidence(0) | probably_damaging(1) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
HSPA1A | SNV | Missense_Mutation | novel | c.4G>A | p.Ala2Thr | p.A2T | P0DMV8 | protein_coding | tolerated_low_confidence(0.08) | benign(0.226) | TCGA-AX-A0J1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
HSPA1A | SNV | Missense_Mutation | novel | c.4G>A | p.Ala2Thr | p.A2T | P0DMV8 | protein_coding | tolerated_low_confidence(0.08) | benign(0.226) | TCGA-AX-A1C5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unspecific | Carboplatin | SD |
HSPA1A | SNV | Missense_Mutation | novel | c.1771N>A | p.Glu591Lys | p.E591K | P0DMV8 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.999) | TCGA-EO-A3AV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | CR |